AU2013311714C1 - Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases - Google Patents

Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases Download PDF

Info

Publication number
AU2013311714C1
AU2013311714C1 AU2013311714A AU2013311714A AU2013311714C1 AU 2013311714 C1 AU2013311714 C1 AU 2013311714C1 AU 2013311714 A AU2013311714 A AU 2013311714A AU 2013311714 A AU2013311714 A AU 2013311714A AU 2013311714 C1 AU2013311714 C1 AU 2013311714C1
Authority
AU
Australia
Prior art keywords
deficiency
thr
gly
glu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013311714A
Other languages
English (en)
Other versions
AU2013311714A1 (en
AU2013311714B2 (en
Inventor
Bo Akerstrom
Magnus Gram
Lena Rosenlof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guard Therapeutics International AB
Original Assignee
A1M Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma AB filed Critical A1M Pharma AB
Publication of AU2013311714A1 publication Critical patent/AU2013311714A1/en
Application granted granted Critical
Publication of AU2013311714B2 publication Critical patent/AU2013311714B2/en
Publication of AU2013311714C1 publication Critical patent/AU2013311714C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013311714A 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases Ceased AU2013311714C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201270538 2012-09-05
DKPA201270538 2012-09-05
DKPA201270557 2012-09-12
DKPA201270557 2012-09-12
PCT/EP2013/068270 WO2014037390A1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Publications (3)

Publication Number Publication Date
AU2013311714A1 AU2013311714A1 (en) 2015-03-12
AU2013311714B2 AU2013311714B2 (en) 2017-10-12
AU2013311714C1 true AU2013311714C1 (en) 2018-01-25

Family

ID=49162118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013311714A Ceased AU2013311714C1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Country Status (21)

Country Link
US (1) US10226507B2 (enExample)
EP (1) EP2900254B1 (enExample)
JP (2) JP2015533790A (enExample)
KR (1) KR20150047510A (enExample)
CN (1) CN104661673A (enExample)
AU (1) AU2013311714C1 (enExample)
BR (1) BR112015003957A2 (enExample)
CA (1) CA2881321A1 (enExample)
DK (1) DK2900254T3 (enExample)
EA (1) EA028963B1 (enExample)
ES (1) ES2599034T3 (enExample)
HR (1) HRP20161364T1 (enExample)
HU (1) HUE030559T2 (enExample)
IN (1) IN2015DN00515A (enExample)
MX (1) MX357656B (enExample)
NZ (1) NZ629621A (enExample)
PL (1) PL2900254T3 (enExample)
PT (1) PT2900254T (enExample)
SG (1) SG11201500669SA (enExample)
WO (1) WO2014037390A1 (enExample)
ZA (1) ZA201500547B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン
CA3014850A1 (en) * 2016-02-25 2017-08-31 A1M Pharma Ab Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media
BR112018068522A2 (pt) * 2016-03-18 2019-01-22 A1M Pharma Ab novas proteínas derivadas de alfa-1-microglobulina e seu uso
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN110452980B (zh) * 2019-09-23 2023-07-28 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006809A2 (en) * 2008-07-18 2010-01-21 Akerstroem Bo Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416906A (pt) * 2003-11-26 2007-01-16 Sanofi Aventis Deutschland proteinúria tubular como um indicador para risco cardiovascular elevado
DK2111555T3 (da) * 2007-02-12 2013-09-02 A1M Pharma Ab Diagnosticering af præeklampsi
SI2300614T1 (sl) * 2008-02-04 2016-02-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metode in sestavki za zdravljenje mitohondrijskih motenj

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006809A2 (en) * 2008-07-18 2010-01-21 Akerstroem Bo Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAY, K et al. "Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by a1-microglobulin". PLACENTA, 2011, Vol. 32, pages: 323-332 *

Also Published As

Publication number Publication date
EA201590503A1 (ru) 2015-06-30
JP2018203756A (ja) 2018-12-27
PT2900254T (pt) 2016-10-18
IN2015DN00515A (enExample) 2015-06-26
BR112015003957A2 (pt) 2017-08-08
KR20150047510A (ko) 2015-05-04
DK2900254T3 (en) 2016-08-29
ES2599034T3 (es) 2017-01-31
HUE030559T2 (en) 2017-05-29
AU2013311714A1 (en) 2015-03-12
EA028963B1 (ru) 2018-01-31
AU2013311714B2 (en) 2017-10-12
ZA201500547B (en) 2017-09-27
WO2014037390A1 (en) 2014-03-13
PL2900254T3 (pl) 2017-02-28
HK1210585A1 (en) 2016-04-29
SG11201500669SA (en) 2015-02-27
US20150258171A1 (en) 2015-09-17
MX357656B (es) 2018-07-18
EP2900254B1 (en) 2016-08-03
MX2015002604A (es) 2015-06-10
NZ629621A (en) 2015-09-25
CA2881321A1 (en) 2014-03-13
EP2900254A1 (en) 2015-08-05
JP2015533790A (ja) 2015-11-26
CN104661673A (zh) 2015-05-27
US10226507B2 (en) 2019-03-12
HRP20161364T1 (hr) 2016-12-16

Similar Documents

Publication Publication Date Title
AU2013311714C1 (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
Tang et al. TIMP1 preserves the blood–brain barrier through interacting with CD63/integrin β1 complex and regulating downstream FAK/RhoA signaling
Lim et al. Molecular characterization of the cystine/glutamate exchanger and the excitatory amino acid transporters in the rat lens
US20140309400A1 (en) Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye Syndrome
IL256243A (en) Methods and preparations for treating conditions related to aging
JP5685773B2 (ja) 血管新生および創傷治癒活性がある薬剤
Bollag et al. Dioleoylphosphatidylglycerol accelerates corneal epithelial wound healing
Zhou et al. Secreted glycoprotein BmApoD1 plays a critical role in anti-oxidation and anti-apoptosis in Bombyx mori
JP2022548367A (ja) 眼科障害の処置または防止における使用のための薬剤
WO2012111878A1 (ko) 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
Formichi et al. Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene
KR20050042205A (ko) Ｅｃ ｓｏｄ 및 세포 침투성 ｅｃ ｓｏｄ와 이들의 용도
KR20150140686A (ko) 신증후군 및 관련 병태의 치료 방법
HK1210585B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
Vijayasarathy et al. Organization and molecular interactions of retinoschisin in photoreceptors
RU2812055C1 (ru) Агент для использования при лечении или профилактике офтальмологических расстройств
Jones The role of optic atrophy 1 (OPA1) in the evolution of brain damage after neonatal hypoxic-ischaemic insult
US20190099468A1 (en) Method to protect and seal the ocular surface
EP3397266A1 (fr) Fragment du facteur h pour son utilisation comme agent anti-angiogénique
KR101481741B1 (ko) Ⅰｇｆ­１을 이용한 변형 프리온 단백질에 의해 유도되는 세포자멸사의 억제방법
Alassaf Pregnancy Associated Plasma Protein-aa Is a Novel Regulator of Neuron Survival
Zhonga et al. Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-PI3K-Akt pathway through its SHBG-like region

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 SEP 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 SEP 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired